MINNEAPOLIS, Aug. 28, 2018 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCPINK:PETV), an emerging biomedical device company, is pleased to announce the addition of Daniel P. Collins, Ph.D., as Chief Science Officer (CSO).
Dr. Daniel Collins has over 30 years of medical industry experience. He co-founded CytoMedical Design, LLC in 2012 serving as its Chief Science Officer. Previously, he co-founded BioE, Inc., in 1993 and served as its Executive Vice President, Chief Scientific Officer and Board member. Before founding BioE, Dr. Collins was Director of R&D Systems, Inc.’s Flow Cytometry Products department; Director of Coulter Corporation’s hematology lab within its Immunology division; and Director of the Harrington Cancer Center’s Immunology, Hematology and Oncology specialty laboratory. He also was an assistant professor at Texas Tech University. Additionally, Dr. Collins was awarded a postdoctoral National Institute of Health fellowship in tumor immunology at Wake Forest University. He holds a Doctorate degree in immunoparasitology from Louisiana State University; a Master of Science degree in public health in tropical medicine from Tulane University; and a Bachelor’s degree from Long Island University.
“My role at PetVivo will be to guide the development of the KUSH™ System and derivative products for future Regenerative Medical applications in the Veterinary market and adaptation of those developments for the Human Regenerative Medicine field,” explained Daniel Collins.
Dr. Collins leads the way, not only with the commercialization of the KUSH™ System, but improvements functionally and commercially. His background and years of cellular research and Regenerative Medicine will also start to build the base of PetVivo’s research and development team for the future.
“There has been extensive discussion about the future improvements and research developing new products. The addition of Dr. Collins addresses those opportunities directly. I feel that this is the first of a series of additions to personnel that will ensure the future of PetVivo,” stated Wes Hayne, PetVivo CEO.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes 17 animal and human therapeutics. A portfolio of 20 patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Wes Hayne, CEO
PetVivo Holdings, Inc.
5251 Edina Industrial Blvd
Edina, MN 55439
CEO’s Direct Line:
Source: PetVivo Holdings Inc.